{
  "ticker": "PTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969693",
  "id": "02969693",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250716",
  "time": "0908",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv40qk7dvscg.pdf",
  "summary": "### **Material Information Summary**  \n(Clinical Trial Update Announcement)  \n\n- **First U.S. site initiated** for PTX-100 Phase 2a trial in refractory/relapsed Cutaneous T-Cell Lymphoma (r/r CTCL).  \n- **Site location**: VCU Massey Comprehensive Cancer Center (top-tier U.S. cancer research institution).  \n- **Current enrollment**: 4 patients across 3 Australian sites; U.S. recruitment now open.  \n- **Regulatory status**: PTX-100 holds FDA Orphan Drug and Fast Track Designations for T-Cell Lymphomas.  \n\n**No trading/capital structure impacts identified.**  \n\n*(Note: Omits operational pipeline details, investor briefing invite, and forward-looking disclaimers as non-material to immediate trading decisions.)*",
  "usage": {
    "prompt_tokens": 2696,
    "completion_tokens": 165,
    "total_tokens": 2861,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T23:13:16.694382"
}